Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesRadiation OncologyAetna radiation nononcologic coverage | OpenPayer
    Ask Trek AI about this page
    CurrentAetnaPolicy 0551

    Radiation Treatment for Selected Nononcologic Indications

    Customize your policy alerts

    Sign up for Aetna Policy 0551 alerts

    Get alerted when Policy 0551 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Aetna's coverage stance for radiation treatments used for specified noncancer conditions (e.g., keloids, heterotopic ossification, pterygium, plantar fibromatosis, osteoarthritis) including when therapy is considered medically necessary or experimental; affects providers submitting claims to Aetna.

    Policy Summary
    PayerAetna
    PolicyRadiation Treatment for Selected Nononcologic Indications
    Policy CodePolicy 0551
    Change TypeAnnual review — no material changes
    Effective DateAug 14, 2001
    Last ReviewJun 10, 2027
    Next Review DateJun 10, 2027
    Key ActionObtain prior authorization and document that selection criteria are met before billing radiation procedures for covered nononcologic indications.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    keloid, HO, pterygium, plantar fibromatosis, OAIndications listed
    77402-77778Procedure codes
    >=60OA age threshold
    BED >=30GyKeloid BED cited

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    4.7%Guix et al recurrence

    Coverage Criteria

    Initial coverage criteria

    Covered when ALL of the following are met for each indicated condition:

    Keloids - adjunctive post-excisional radiation: Radiation (low- or high-dose, superficial or interstitial) is medically necessary as an adjunctive therapy immediately following excisional surgery when medical necessity criteria for keloid removal are met.within 7 days

    See CPB 0031 for indications for keloid removal.

    Heterotopic ossification - prophylaxis: Radiation therapy is medically necessary for prevention of heterotopic ossification in persons identified as being at high risk.high-risk features present

    High-risk features include previous heterotopic ossification, ankylosing spondylitis, diffuse idiopathic skeletal hyperostosis or spinal stenosis, unlimited hip motion preoperatively, and head injury.

    Ledderhose disease (plantar fibromatosis): Radiation therapy is medically necessary for treatment when conventional treatments (e.g., tamoxifen, verapamil, and steroid injections) have failed.failure of conventional treatments
    Pterygium - beta irradiation: Use of beta irradiation is medically necessary for prevention of primary or recurrent pterygium in cases that cannot be managed medically.medical management not possible or failed

    Strontium-90 regimens and low-dose fractionation schedules are discussed in background evidence.

    Osteoarthritis: Radiation therapy is medically necessary when all of the following are met: member is at least 60 years of age; inadequate response to non-pharmacologic therapies; inadequate response, intolerance, or contraindication to pharmacologic therapies; and consultation/evaluation by an orthopedic surgeon deemed disease advanced enough for joint replacement but the member is medically inoperable.all criteria present

    Experimental, investigational, or unproven

    Experimental/Investigational/Unproven: TRASER device for nasal telangiectasias; ablative radiotherapy for cardiac arrhythmia; and other listed modalities are considered experimental, investigational, or unproven because effectiveness has not been established.

    See related CPBs for additional context.

    Evidence-supported uses and emerging/experimental indications

    Evidence summaries and suggested indications from the literature

    Keloids - HDR/LDR brachytherapy evidence: Multiple series report HDR/LDR adjuvant brachytherapy after surgical excision reduces recurrence and yields favorable cosmetic outcomes; reported fractionation examples include 12 Gy in 4 fractions and 18 Gy in 6 fractions; studies report low recurrence and good cosmetic results when radiation is given promptly after surgery.evidence-based

    References include Guix et al, De Cicco et al, van Leeuwen et al.

    Nasal telangiectasias - TRASER: Small trials of the TRASER device report high initial vessel clearance and patient satisfaction with minimal adverse events, but follow-up is limited and sample sizes are small; findings require validation in larger, well-designed studies.preliminary evidence

    Friedman et al 2017; Geddes-Bruce 2018.

    Cardiac arrhythmias - non-invasive radio-ablation:

    Ablative radiotherapy delivered using CPT codes 77373 and 77435 is listed in this Clinical Policy Bulletin as not covered when used for the indications addressed by this policy. Claims submitted using these codes for experimental or unproven indications discussed here (for example, stereotactic/ablative radiotherapy for cardiac arrhythmias) may be denied because effectiveness for those indications has not been established.

    The policy text does not list broad categorical exclusions beyond the specific procedural/code-based exclusion noted elsewhere; however, several clinical uses discussed in the background are characterized as early-stage or investigational and require further validation (examples include noninvasive cardiac radio-ablation for ventricular tachycardia and radiotherapy for drug‑resistant focal epilepsy). These indications are described in the background evidence summaries as preliminary, requiring larger or randomized trials before routine coverage can be assumed.

    This Clinical Policy Bulletin (CPB) provides a summary of Aetna's coverage position for radiation treatments used for selected nononcologic indications. It is intended to assist in administering plan benefits and does not constitute an offer of coverage, medical advice, or a contract. Treating providers remain responsible for medical advice and treatment decisions, and the CPB may be updated over time.

    The policy explicitly considers the TRASER device for nasal telangiectasias and ablative radiotherapy for cardiac arrhythmia to be experimental, investigational, or unproven because their effectiveness has not been established. As such, use of these modalities for the listed indications is not considered medically necessary under this CPB.

    Several therapies discussed in the background are described as having preliminary or limited evidence rather than being explicitly labeled 'not medically necessary' in every instance. For example, single‑fraction SBRT (25 Gy) for refractory ventricular tachycardia and radiotherapy approaches for drug‑resistant focal epilepsy have encouraging case series or systematic reviews but are characterized as early evidence needing prospective validation; the CPB therefore treats them as investigational or requiring further study.

    Coding

    Covered CPT Codes (if selection criteria are met)CPTCovered
    77402-77417Radiation treatment delivery [includes beta irradiation].
    77436Surface radiation therapy; superficial or orthovoltage, treatment planning and simulation-aided field setting.
    77437Surface radiation therapy; superficial, delivery, ≤150 kV, per fraction (eg, electronic brachytherapy).
    77438Surface radiation therapy; orthovoltage, delivery, >150-500 kV, per fraction.
    77439Surface radiation therapy; superficial or orthovoltage, image guidance, ultrasound for placement of radiation therapy fields for treatment of cutaneous tumors, per course of treatment (List separately in addition to code for primary procedure).
    77767-77772Remote afterloading high dose rate radionuclide skin surface brachytherapy, includes basic dosimetry, when performed.
    77778Interstitial radiation source application, complex, includes supervision, handling, loading of radiation source, when performed.
    CPT Codes not covered for listed CPB indicationsCPTNot Covered
    77373Stereotactic body radiation therapy, treatment delivery, per fraction to 1 or more lesions, including image guidance, entire course not to exceed 5 fractions [ablative radiotherapy].
    77435Stereotactic body radiation therapy, treatment management, per treatment course, to 1 or more lesions, including image guidance, entire course not to exceed 5 fractions [ablative radiotherapy].
    ICD-10 Codes covered if selection criteria are metICD-10Covered
    L91.0Hypertrophic scar [keloid].
    M15.0-M19.93Osteoarthritis.
    M08.1Juvenile arthritis code listed (document context unclear).
    M45.0-M45.9Ankylosing spondylitis.
    M48.00-M48.08Spinal stenosis.
    M72.2Plantar fascial fibromatosis.
    S06.0x0A-S06.9x9SIntracranial injury (head injury range).
    ICD-10 Codes not covered for listed CPB indicationsICD-10Not Covered
    I78.1Nevus.
    I49.01-I49.9Other cardiac arrhythmias.
    Codes not specified in this portionmixed
    No codes listed
    Age threshold for osteoarthritis
    Age thresholdMember must be at least 60 years of age
    Prior therapies requiredInadequate response to non-pharmacologic therapies (e.g., physical therapies)
    Pharmacologic therapy requirementInadequate response, intolerance, or contraindication to pharmacologic therapies (e.g., topical/systemic analgesics, intra-articular glucocorticoids)
    Surgical evaluationOrthopedic surgeon evaluation documenting disease advanced enough for joint replacement but patient deemed medically inoperable
    HDR brachytherapy fractionation example

    Provider Actions and Documentation

    Prior Authorization

    Prior authorization expected for listed radiation procedure codes

    Prior authorization is implied for the CPT/HCPCS codes listed as covered (e.g., 77402-77417, 77436-77439, 77767-77772, 77778) when those services are billed for the CPB-covered indications; selection criteria in the policy must be met before treatment is considered medically necessary.

    • Covered CPT ranges: 77402-77417, 77436-77439, 77767-77772, 77778 (see coding section).
    • Ensure documentation supports that the member meets the condition-specific selection criteria in the policy (e.g., keloid excision within 7 days, osteoarthritis age and prior therapy requirements, high-risk features for HO).
    Prior Authorization

    No explicit prior-authorization process stated for experimental indications

    The policy text includes clinical series and background but does not specify additional or separate prior-authorization rules or a distinct prior authorization process tied to specific experimental indications described in the background.

    • Case series (e.g., single-fraction 25 Gy SBRT for cardiac VT) are described in background without stating a separate PA requirement or defined PA pathway for those experimental uses.

    Background

    Keloids are benign, proliferative dermal scars with a high likelihood of recurrence after excision. The CPB states that postoperative radiation (low‑ or high‑dose, superficial or interstitial) given promptly after excision (within 7 days) reduces recurrence and is considered medically necessary when keloid removal itself meets medical necessity criteria (see CPB 0031).

    Definitions

    BED for keloid prevention
    BED thresholdBiologically effective dose (BED) of at least 30 Gy correlated with successful prevention of keloid recurrence
    Example regimens achieving BED ≥30 GySingle 13 Gy; 2 × 8 Gy; or 3 × 6 Gy (or 27 Gy at low-dose rate)
    Timing relative to surgeryRadiation should be administered within 2 days following surgery (policy notes within 7 days for adjunctive therapy)
    HDR brachytherapy (keloids)
    HDR post-excision regimen12 Gy total delivered as 4 fractions of 3 Gy in 24 hours (administered within 30–60 minutes of surgery in Guix et al)
    HDR definitive regimen18 Gy total delivered as 6 fractions of 3 Gy over 1.5 days

    Revision History

    2001-08-14effective_date

    Policy became effective.

    2026-07-30last_reviewLatest

    Policy last reviewed on 07/30/2026.

    2027-06-10next_review

    Next scheduled policy review date is 06/10/2027.

    Policy Summary
    PayerAetna
    PolicyRadiation Treatment for Selected Nononcologic Indications
    Policy CodePolicy 0551
    Change TypeAnnual review — no material changes
    Effective DateAug 14, 2001
    Last ReviewJun 10, 2027
    Next Review DateJun 10, 2027
    Key ActionObtain prior authorization and document that selection criteria are met before billing radiation procedures for covered nononcologic indications.
    SourceLink
    On This Page
    Coverage CriteriaCodingProvider Actions and DocumentationBackgroundDefinitionsRevision History
    Case series (n=5) report marked reduction in ventricular tachycardia episodes after non-invasive electrophysiology-guided radio-ablation delivered as a single 25 Gy fraction; these preliminary results require confirmation in larger trials to establish safety and efficacy.
    experimental/early evidence

    Cuculich et al 2017 and subsequent case reports/reviews.

    Ledderhose disease (plantar fibromatosis): Electron and ortho-voltage RT series report stabilization or improvement of symptoms in the majority of early-stage patients using dose schemes such as 21 Gy (3 Gy ×7) and 30 Gy (3 Gy ×10); re-irradiation can be effective for in-field progression.supportive evidence

    Schuster et al 2015; DEGRO summaries.

    Osteoarthritis - low-dose radiotherapy (LDRT): Systematic reviews and narrative reviews report that LDRT can provide pain relief in some patients refractory to conventional therapies, typically using low-fraction doses (e.g., 0.5 Gy per fraction); randomized trial results are mixed and patient/joint selection is important.investigational/conditional

    Yu et al 2021; Dove et al 2022.

    Radiotherapy for drug-resistant non-neoplastic focal epilepsy: Level 4 evidence from systematic review suggests radiotherapy may reduce seizure frequency in some adults with drug-resistant focal epilepsy, but risks (radiation necrosis, cysts, edema) and need for prospective randomized trials limit current recommendations.experimental

    Eekers et al 2018.

    HDR example (post-excision)
    Total dose 12 Gy delivered as 4 fractions of 3 Gy each over 24 hours (09:00, 15:00, 21:00, 09:00 next day)
    HDR example (definitive)Total dose 18 Gy delivered as 6 fractions of 3 Gy each over 1.5 days (three fractions per day)
    Timing relative to surgeryWhen used after excision, HDR brachytherapy was administered within 30 to 60 minutes of surgery in the reported series
    Cardiac radio-ablation dose
    Cardiac radio-ablation dose exampleSingle fraction of 25 Gy (non-invasive SBRT as reported by Cuculich et al)
    Patient cohort (example study)Series described 5 patients with high-risk, refractory ventricular tachycardia
    Assessment methodEfficacy assessed by ICD-recorded VT episodes with safety via serial cardiac and thoracic imaging
    Typical whole dose ranges in German series
    Mean whole dose - degenerative disordersLess than 10 Gy
    Mean whole dose - hyper-proliferative diseasesApproximately 25 Gy
    Mean whole dose - functional disordersApproximately 15 Gy
    Mean whole dose - stereotactic RTLess than 50 Gy
    LDRT OA fraction
    Common LDRT fraction sizeTypically 0.5 Gy per fraction
    Typical use caseUsed in low-dose radiotherapy protocols for osteoarthritis in patients refractory to conventional therapies
    Follow-up and retreatmentFollow-up assessments guide need for retreatment; protocols vary across studies
    Prior Authorization

    Policy does not define additional CPT/HCPCS PA-trigger codes

    Across the policy background and history there are no explicit, additional lists of CPT/HCPCS codes that trigger prior authorization beyond the covered and not-covered code listings provided in the coding section.

    • Policy coding tables list covered and not-covered CPT codes but do not add separate PA-trigger code lists in the narrative background or policy history.
    Step Therapy

    Stepwise treatment required before radiation for osteoarthritis

    For osteoarthritis, radiation therapy is considered only after a stepwise trial of therapies: inadequate response to non-pharmacologic therapies, then inadequate response/intolerance/contraindication to pharmacologic therapies, and after orthopedic surgical evaluation that deems the patient medically inoperable for joint replacement.

    • Document inadequate response to non-pharmacologic therapies (e.g., physical therapy, exercise).
    • Document inadequate response, intolerance, or contraindication to pharmacologic therapies (e.g., topical/systemic analgesics, intra-articular glucocorticoids).
    • Include orthopedic surgeon consultation indicating disease advanced enough for joint replacement but patient is medically inoperable.
    Step Therapy

    Conservative therapies must be tried before low-dose radiotherapy for OA

    Background and guidance indicate low-dose radiotherapy (LDRT) for osteoarthritis is intended for patients refractory to conventional conservative therapies; providers should document trials of exercise, physical therapy, and NSAIDs (or intolerance) before LDRT is considered.

    • Record conservative therapies attempted and duration (e.g., exercise, physical therapy, NSAIDs).
    • Document rationale for selecting LDRT (joint selection, impact on quality of life, prior therapy response).
    Note
    Documentation Required

    Keloid excision + postoperative radiation: document CPB 0031 indications and treatment within 7 days

    When postoperative radiation is given for keloids, documentation must show the excision met medical necessity criteria for keloid removal per CPB 0031 and that radiation was delivered within the policy-specified window (within 7 days after excision).

    • Reference CPB 0031 to demonstrate medically necessary indication for keloid excision.
    • Document timing of radiation relative to excision (treatment within 7 days per policy).
    • Include radiation regimen details (e.g., HDR brachytherapy schedules cited in background such as 12 Gy in 4 fractions or 18 Gy in 6 fractions when applicable).
    Documentation Required

    Osteoarthritis documentation: age and failed therapies required

    For osteoarthritis claims, include documentation that the member is at least 60 years old and that prior non-pharmacologic and pharmacologic therapies failed or were not tolerated; also include the orthopedic surgeon evaluation stating the patient is medically inoperable for joint replacement.

    • Member age (≥ 60 years).
    • Records of non-pharmacologic therapy attempts and outcomes.
    • Records of pharmacologic therapy trials, intolerances, or contraindications.
    • Orthopedic surgeon consultation findings and operative candidacy determination.
    Documentation Required

    HO prophylaxis: document high-risk features to support medical necessity

    When radiation is used for heterotopic ossification (HO) prophylaxis, document the presence of high-risk features (for example: prior HO, ankylosing spondylitis, diffuse idiopathic skeletal hyperostosis, spinal stenosis, unlimited pre-op hip motion, or head injury) to support medical necessity.

    • List and document high-risk features present in the patient.
    • Include surgical context and timing of prophylactic radiation relative to surgery as applicable.
    Documentation Required

    Document treatment regimens, dose schemes, and follow-up schedules in the record

    Medical records should include treatment reports specifying the regimen, dose/fractionation scheme, and planned follow-up schedule; background examples (HDR brachytherapy fractionation, electron RT schemes, LDRT fraction sizes) are referenced and should be recorded in the chart when used.

    • Specify radiation modality, total dose, fractions, and timing (e.g., HDR brachytherapy 12 Gy in 4 fractions; electron RT schemes 21 Gy in 7 fractions or 30 Gy in 10 fractions; LDRT typically 0.5 Gy/fraction).
    • Document follow-up plan and outcome assessments used in cited series (e.g., follow-up intervals used in Guix et al.).
    Note

    Policy history provided — no extra documentation obligations in history section

    Policy history and review links are provided in the document header and history section, but these sections do not impose additional clinical documentation requirements beyond those already stated.

    • Review dates and links are for reference; they do not change the documentation expectations in the clinical criteria.
    Billing Rule

    Coding-related denial risk for not-covered ablative/SBRT CPT codes

    Claims submitted with CPT codes listed as not covered for the CPB indications (for example, ablative radiotherapy codes 77373 and 77435 used for cardiac arrhythmia) are at risk of denial when those experimental/unproven indications are billed.

    • Do not bill ablative/SBRT CPTs 77373 or 77435 for cardiac arrhythmia indications described in this CPB.
    • Ensure coding matches the modality and indication supported by the policy's covered code list and clinical criteria.
    Note

    Background case-series do not constitute PA or denial triggers

    Several background sections and series describe clinical experience without stating specific prior-authorization or denial triggers; these background-only descriptions do not themselves create authorization rules.

    • Treat background reports (case series, observational data) as clinical context rather than PA policy language.
    • Rely on the policy's coverage criteria and coding tables to determine medical necessity and appropriate billing.
    Note
    Reported outcomesLow recurrence (4.7% at 7 years overall in Guix et al) and generally good/excellent cosmetic results
    HDR brachytherapy
    HDR definition and examplesHigh-dose-rate interstitial brachytherapy delivering concentrated radiation in multiple fractions (examples: 12 Gy in 4 fractions or 18 Gy in 6 fractions)
    SettingUsed as adjunctive therapy post-excision (administered soon after surgery) or as definitive treatment in select cases
    Advantages notedFavored for selective tissue dosing, outpatient delivery, and favorable dose distribution compared with superficial X-rays or LDR techniques
    Stereotactic radio-ablation / SBRT for cardiac arrhythmia
    Technique descriptionNon-invasive electrophysiology-guided stereotactic radio-ablation (SBRT) targeting arrhythmogenic scar regions
    Dose exampleSingle-fraction SBRT of 25 Gy delivered while patient awake (Cuculich et al)
    Evidence levelCase series (n=5) with marked reduction in VT episodes; safety and efficacy require validation in larger trials
    TRASER
    TRASER definitionTotal Reflection Amplification of Spontaneous Emission Radiation — a configurable narrow‑spectrum light‑based device evaluated for nasal telangiectasias
    Study findingsSmall trial reported procedure success with 100% of efficacy population achieving primary end-point at end of treatment; majority cleared after a single treatment
    Evidence limitationsSmall sample sizes and short follow-up; authors note need for validation by well‑designed studies
    Ledderhose disease (plantar fibromatosis)
    Condition descriptionLedderhose disease (plantar fibromatosis) is a benign hyperproliferative disorder of the plantar fascia causing nodules that may be painful and functionally limiting
    Typical RT dose schemesCommonly reported dose schemes include 21 Gy (3 Gy × 7 fractions) and 30 Gy (3 Gy × 10 fractions, with a break after 15 Gy)
    Outcomes reportedRT stabilized or improved symptoms in majority of early‑stage patients; overall patient‑reported success ~94% in one series with re‑irradiation an option for in‑field progression
    Clinical Policy Bulletin definition
    PurposeClinical Policy Bulletins assist Aetna in administering plan benefits but do not constitute offers of coverage or medical advice
    ScopeContains general descriptions of benefits; treating providers are responsible for medical advice and treatment of members
    Review datesEffective date 08/14/2001; Last review 07/30/2026; Next review 06/10/2027